NCT04917523View on ClinicalTrials.gov

Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above

PHASE3CompletedINTERVENTIONAL
Enrollment

1,800

Participants

Timeline

Start Date

July 2, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

April 29, 2022

Conditions
COVID-19 PneumoniaCOVID-19
Interventions
BIOLOGICAL

SARS-CoV-2 Vaccine (Vero Cell), Inactivated

0.5 mL per dose, containing 6.5U inactivated SARS-CoV-2 antigen

Trial Locations (1)

51900

Sheikh Khalifa Medical City, SEHA, Abu Dhabi

All Listed Sponsors
collaborator

Beijing Institute of Biological Products Co Ltd.

INDUSTRY

lead

China National Biotec Group Company Limited

INDUSTRY